Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
Status:
Withdrawn
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this prospective interventional study is to assess whether adjunctive
verteporfin photodynamic therapy (PDT) is effective for the treatment of persistent disease
activity in neovascular age-related macular degeneration (NV AMD), as compared to anti-VEGF
therapy (aflibercept) alone. This study will enroll individuals with NV AMD who have
persistent disease activity in spite of either loading dose (initial 3-5 anti-VEGF
treatments) or maintenance (established course) anti-VEGF therapy to determine whether PDT
can improve disease activity, facilitate sustained visual acuity gains, and decrease burden
of frequent anti-VEGF treatments for affected patients. Risks of study are related to
treatment with study drugs: intravenous verteporfin, intravitreal triamcinolone acetonide,
and intravitreal aflibercept. All have been studied extensively in clinical trials and are
established treatments used routinely in NV AMD. Adverse events will be monitored by the
principal investigator and study team.